Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
The FDA approved a higher-dose Wegovy (7.2 mg) for obese adults who need more weight loss, showing 19% average weight reduction in trials.
The FDA has approved a higher-dose version of Wegovy (7.2 mg), now available in April, for adults with obesity who’ve tolerated the 2.4 mg dose and need further weight loss.
Clinical trials showed the higher dose led to an average 19% body weight loss over 17 months, compared to 16% on the lower dose, with 31% achieving at least 25% weight loss.
The drug is used with diet and exercise, and side effects including nausea, vomiting, constipation, and a burning skin sensation occurred more frequently.
Serious adverse events were reported in nearly 7% of users.
European regulators had already approved the higher dose in February.
Pricing details are pending.
La FDA aprobó una dosis más alta de Wegovy (7.2 mg) para adultos obesos que necesitan más pérdida de peso, mostrando una reducción de peso promedio del 19% en los ensayos.